Creative Medical Technology Holdings, Inc. (CELZ) AI Stock Analysis

Creative Medical Technology Holdings, Inc., based in Phoenix, Arizona, is a biotechnology company focused on the development and application of adult stem cell treatments across immunology, urology, orthopedics, and neurology. Its flagship product offerings include CaverStem, a therapy designed to treat erectile dysfunction by rejuvenating tissues involved in erectile function. The company has also introduced FemCelz to improve female genital sensitivity and address dryness, StemSpine to target chronic lower back pain through stem-cell-driven tissue regeneration, ImmCelz to improve neurological recovery in stroke patients, and OvaStem to address female health concerns.

Over the five-year period from FY2020 to FY2025, revenue contracted at a CAGR of 48.4%. Annual revenue fell from $87,754 in FY2021 to $88,600 in FY2022, then dropped to $9,000 in FY2023, $11,000 in FY2024, and $6,000 in FY2025. In FY2025, the company posted an operating margin of -102380.2% and a net loss of -$6.0M, or an EPS of -$2.59, while spending $2.3M on research and development. For the trailing twelve months ended June 30, 2026, revenue stood at $3,000 with an operating margin of -208004.4% and an EPS of -$2.07, despite quarterly earnings growth of 358.9% year-over-year.

As of June 30, 2026, Creative Medical Technology Holdings had $8.7M in cash and short-term investments, total assets of $9.4M, and shareholders' equity of $8.7M. The company reported a current ratio of 12.91. In FY2025, operating cash flow was -$5.9M and free cash flow was -$5.9M. Capital expenditures were $5, and the company completed $10,000 in share buybacks. Over the five-year period, its share count grew by 484.0%.

CELZ closed at $0.74 on October 16, 2026, giving it a market capitalization of $5.6M and an enterprise value of -$2.6M. The stock trades at a price-to-book multiple of 0.7x and an enterprise value to revenue multiple of 753.5x. By comparison, the median of its US-listed Healthcare peers trades at a price-to-sales multiple of 4.1x and an EV to EBITDA multiple of 12.0x. CELZ shares fell 81.6% over the past year and 99.1% over five years, trailing the S&P 500 (SPY), which gained 16.8% and 83.0% over those respective periods.

One analyst covers CELZ, issuing a Strong Buy rating with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $20.00, which is 2599.1% above the last closing price of $0.74. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.18 on $0 in revenue. For the following fiscal year, the consensus EPS estimate is -$0.88 on $0 in revenue. CELZ beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 6, 2026.

This page is an AI-written research summary of Creative Medical Technology Holdings, Inc. (CELZ). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CELZ income statement, CELZ balance sheet, CELZ key metrics, CELZ analyst forecast, CELZ chart. See the CELZ stock overview for the latest quote and news.